ARIA
Library/metabolic/Semaglutide

Semaglutide

FDA Approved✓ WADA Permitted

Wegovy / Ozempic

metabolic✓FDA ApprovedGLP-1 receptor agonist

FDA-approved GLP-1 receptor agonist for type 2 diabetes (Ozempic) and chronic weight management (Wegovy 2.4mg weekly). Mean 14.9-16.8% body weight loss in STEP trials.

Confidence
98%
Half-Life ~7 days
Cost ~$1400/mo
Quick Reference
Routesubcutaneous
MechanismActivates GLP-1 receptor → glucose-dependent insulin secretion, reduced glucagon...
SequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
Mol. Weight4113.6 Da
Reviewed2026-07-08

Mechanism of Action

Activates GLP-1 receptor → glucose-dependent insulin secretion, reduced glucagon, slowed gastric emptying, hypothalamic appetite suppression. Cardiovascular and renal protective effects.

Dosing Protocol

Wegovy: 0.25mg/wk x4 → 0.5mg/wk x4 → 1.0mg/wk x4 → 1.7mg/wk x4 → 2.4mg maintenance.

Key Studies

2021

STEP 1: Semaglutide 2.4mg in obesity

PMID 33555916rct
2026

GLP-1 RA reduces knee OA arthroplasty risk

PMID 42229941cohort
2026

GLP-1 RA and hair loss risk

PMID 42249225cohort
2026

Semaglutide pharmacovigilance WHO-VigiAccess

PMID 42152320pharmacovigilance

Adverse Effects

Nausea (44%)Vomiting (24%)Diarrhea (30%)Constipation (24%)Abdominal painInjection site reactionsPancreatitis (rare)Gallbladder diseaseTelogen effluvium (possible)GI obstruction (rare)

Contraindications

  • Personal/FHx medullary thyroid carcinoma
  • MEN2 syndrome
  • Hypersensitivity
  • Pregnancy

Storage

Refrigerate at 2-8°C. Protect from light. Once opened, use within 56 days.

Clinical Applications

  • ["weight_management"
  • "type_2_diabetes"
  • "metabolic_syndrome"
  • "pre_surgical_weight_optimization"]